Table 2.

Main ongoing clinical trials

Trial name (identifier)	Phase and status	Treatment scheme	Patient population
NCT01125566 (LUX Breast 1)	Phase 3: recruiting	Vinorelbine + trastuzumab vs vinorelbine + afatinib	I and II line metastatic breast cancer patients
NCT01325428	Phase 2: recruiting	Afatinib alone or in combination with vinorelbine	HER2 positive locally advanced or metastatic inflammatory breast cancer
NCT01441596 (LUX Breast 3)	Phase 2: recruiting	Afatinib alone or in combination with vinorelbine	HER2 positive breast cancer with brain metastasis after trastuzumab/lapatinib therapy
NCT00826267	Phase 2: completed	Afatinib monotherapy vs trastuzumab vs lapatinib	HER2 positive treatment-naïve stage IIIa breast cancer patients (neoadjuvant setting)
NCT00708214	Phase 2: completed	Afatinib in combination with letrozole	Hormone resistant metastatic breast cancer patients
NCT00425854	Phase 2: completed	Afatinib in monotherapy	HER2 negative metastatic breast cancer, after maximum 2 lines of chemotherapy
NCT00950742	Phase 1: active, not recruiting	Afatinib in combination with trastuzumab	HER2 positive advanced refractory breast cancer patients